Navigation Links
Novartis Class Awarded $250 Million in Punitive Damages
Date:5/19/2010

n">Grant Morris, of Washington, D.C. 

"This is a just award, and one richly deserved by Novartis' female sales reps. The 5,600 women in the class endured egregious gender discrimination for years. All the while, the company did nothing, even after being warned time after time about the deep-seated culture of discrimination at the company," said Mr. Sanford. "What the jury did here today was the right thing—not only for the women in the class but also for working women around the country who deserve to work in an environment free of discrimination."

"The jury's decision speaks to Novartis with a force far greater than any single voice.  For the thousands of women across the country who suffered discrimination, finally the time has come that Novartis must hear and recognize the depth of its injustice," said Katherine Kimpel. "Corporations cannot violate our federal equal employment laws and get away with it. Jurors like the ones who ruled today will not stand for it. If you profit off of the American people, you have to abide by our civil rights laws."  

Although several of Novartis' witnesses claimed during the trial that the company had a "zero tolerance policy" for discrimination, those witnesses each admitted that the company's managers were never terminated or demoted, even when complaints of discrimination were substantiated by its own HR department.

Steven Wittels said of today's victory, "All of the brave women who testified have played a role in standing up to this company's discriminatory treatment of women, and we are gratified to have been able to help them in this quest.  We all hope that no female employee in Novartis or any other large corporation will ever have to endure what these women endured while
'/>"/>

SOURCE Sanford Wittels & Heisler LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
5. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
6. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
7. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
10. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 Elsevier , ... products and services, today announced the highlights of its ... 2014 Journal Citation Reports® (JCR) published by Thomson Reuters, ... from 2013 to 2014, ahead of the aggregate across ... rank in 62 subject categories, up from 61 in ...
(Date:6/26/2015)... June 26, 2015  A San Francisco company, Pembient, ... with synthetic rhino horn: beer in China ... . In response to the emerging industry, two ... and sale of synthetic rhino horn.  ... Save the Rhino International (SRI) released a ...
(Date:6/26/2015)... The report "Biolubricants Market by ... fluids, Chainsaw oils, Mold Release Agents), End Use (Industrial, ... trends and Forecasts to 2020" published by MarketsandMarkets, The ... 2020 at a CAGR of 6.27% between 2015 and ... and   66 Figures spread through 170 Pages and ...
(Date:6/25/2015)... ... 25, 2015 , ... The American Brain Tumor Association announced ... Family Conference, Providing and Pursuing Answers: Advances in Research, Treatment and Care. The ... July 24-25, 2015. , “As advances in research accelerate the arrival of precision ...
Breaking Biology Technology:Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3Nationally Recognized Brain Tumor Experts to Speak at American Brain Tumor Association Patient and Family Conference 2
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... phase 3 study at the 47th Annual Meeting of ... PA. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , ... Infectious Diseases, Chair of the Infection Prevention and Control ...
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading ... cells, announced today it will report financial results for the ... 5, 2009. , Company,s Conference Call and ... Thursday, November 5, 2009 at 2:00 PM Pacific (5:00 PM ...
... LAKE, N.J., Oct. 30 Eisai Inc. today announced ... with eribulin mesylate (E7389), discovered and developed by the ... cancer. , This global Phase III study, known as ... Versus E7389), was an open-label, randomized, parallel two-arm, multi-center ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 4
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... to the future of the oceans, suggests a new report ... 8th issue of Current Biology, a publication of Cell Press. ... first evidence that the health of the deep sea, as ... with the diversity of species living there. For the ...
... in the numbers of copies of genes, occur when ... stalls and then switches to a different genetic template, ... in a report that appears today in the journal ... Stalling and Template Switching, said Dr. James R. Lupski, ...
... research published online this week in the open-access journal ... the fruit fly, and comes to a surprising new ... on the presence of the Y chromosome, which is ... But other animal groups have evolved different systems. James ...
Cached Biology News:Deep-sea species' loss could lead to oceans' collapse, study suggests 2Copy number variation may stem from replication misstep 2Copy number variation may stem from replication misstep 3
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... The product contains 5 ml of ... cells from Dynabeads CD19 (Pan B). ... CD19 (Pan B) and released with ... unaltered. Cells are suitable for applications ...
Request Info...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Biology Products: